The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) with chemotherapy, followed by durvalumab alone, for advanced or recurrent...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib (Augtyro) for...
Kinase inhibitor trametinib may spare patients from intensive treatments, such as stem cell transplant, for An aggressive form of blood cancer in Small Children. Researchers say they have found a new way to treat...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for adults and children 2 years and...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration (FDA) has approved imetelstat (Rytelo) for patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS)...
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Young adults often ignore telltale signs of colorectal cancer, and more evidence supports active surveillance for low-risk prostate cancer.
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with...
Aspirin appears to activate an immune response against colorectal cancer in the early stages of the disease.
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET alterations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to selpercatinib (Retevmo)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More